Cited 0 times in Scipus Cited Count

Clinical value of pretreatment serum cyfra 21-1 and SCC Ag levels in cervical cancer patients

DC Field Value Language
dc.contributor.author정, 태영-
dc.contributor.author유, 희석-
dc.contributor.author장, 기홍-
dc.contributor.author전, 미선-
dc.contributor.author박, 찬희-
dc.contributor.author박, 영한-
dc.contributor.author정, 두용-
dc.contributor.author오, 기석-
dc.date.accessioned2012-01-18T07:22:04Z-
dc.date.available2012-01-18T07:22:04Z-
dc.date.issued1999-
dc.identifier.issn0494-4755-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/5302-
dc.description.abstractObjectives: SCC Ag(Squamous cell carcinoma antigen) is so far the most useful tumor marker in assisting clinical diagnosis of cervical cancer and follow-up after therapy. Elevated levels of cytokeratin 19-fragments(CYFRA 21-1) have recently been detected in large proportion of patients with non small cell cancer of the lung, and in particular those with squamous cell carcinoma. This study is to assess the clinical efficacy of CYFRA 21-1 with SCC Ag as the clinicopathologic parameter in cervical cancer.
Method: Retrospective analysis of the serum tumor markers CYFRA 21-1 & SCC Ag in eighty cervical cancer patients was performed.
Results: Cut off values for SCC Ag & CYFRA 21-1 were 1.94 ng/ml, 3.11 ng/ml respectively. Using the cut-off point, the sensitivity, specificity, positive predictive value(PPV), and negative predictive value(NPV) of serum SCC were 55, 95, 97, 46%, respectively. Serum CYFRA 21-1 showed a sensitivity of 45%, specificity of 91%, PPV of 87%, and NPV of 55%. The combination of SCC and CYFRA 21-1 increased the sensitivity to 62%, with a specificity, PPV, and NPV of 72, 75, 58%. Serum levels of both markers were compared with tumor stage, lesion size and were significantly related. In FIGO stage Ib-IIa, the serum levels of SCC Ag & CYFRA were 2.2±3.9, 2.5±3.6 ng/ml and in FIGO stage IIb-IV, 12.2±15.2, 10.8±11.2 ng/ml. In ≤4cm of lesion size the serum levels of SCC Ag & CYFRA were 3.3±9.0, 4.5±7.6 ng/ml and in >4cm of lesion size, 11.8±11.9, 7.7±9.3 ng/ml.
Conclusion: These data seems to show that serum CYFRA 21-1 may be of additional value in assessing the state of disease in some patients with cervical cancer. The prediction of recurrent cervical cancer with SCC Ag were improved by the combination with CYFRA 21-1 but further investigation is needed.
en
dc.description.abstract목적: 폐(lung)의 비소세포암(non-small cell cancer) 뿐만 아니라 편평상피암의 진단에 사용되고 있는 CYFRA 21-1의 혈청치가 자궁경부암의 추적관찰 및 재발암을 예측하는데 있어 혈청종양표지물질로서 가장 널리 사용되고 있는 Squamous cell carcinoma antigen(SCC Ag)과 더불어 임상병리학적 변수로서의 부가적 가치에 대한 여부를 알아보고자 하였다.
연구방법: 1995년 11월부터 1997년 7월까지 아주대학교병원 산부인과에 내원한 중에서 CYFRA 21-1과 SCC Ag을 측정한 80명의 자궁경부암 환자와 정상 또는 부인과 양성질환자 59명을 대조군으로 후향적 연구를 하였다.
결과: 1. ROC curve에 의한 혈청 SCC Ag과 CYFRA 21-1의 정상 cut-off value는 각각 1.94ng/ml, 3.11ng/ml였다. 2. Cut-off point에 의한 SCC Ag의 민감도, 특이도, 양성예측율, 음성예측율은 각각 55, 95, 97, 46%, CYFRA 21-1은 각각 45, 91, 87, 55% 였으며 두 물질의 병용측정시 민감도는 62%로 증가하였고 특이도, 양성예측율, 음성예측율은 각각 72, 75, 58% 였다. 3. FIGO stage Ib-IIa 의 SCC Ag과 CYFRA 21-1의 혈청치는 각각 2.2±3.9ng/ml, 2.5±3.6ng/ml 였으며 stage IIb-IV 는 각각 12.2±15.2ng/ml, 10.8±11.2ng/ml 였다(p<0.05). 4. 종양종괴의 크기가 4cm 이하인 경우 SCC Ag과 CYFRA 21-1의 혈청치는 각각 3.3±9.0ng/ml, 4.5±7.6ng/ml 였으며 4cm 보다 큰 경우는 각각 11.8±11.9ng/ml, 7.7±9.3ng/ml 였다(p<0.05).
결론: CYFRA 21-1의 혈청치의 측정은 자궁경부암을 추적관리하는데 있어 SCC Ag 보다 민감도는 낮으나 병행측정시 보다 높은 민감도를 보이며 자궁경부암의 병기, 종양의 크기 등을 예측하는데 있어서 부가적 가치가 있는 물질로 사용가능할 것으로 사료된다. 또한 치료 후 추적관찰 중 재발암을 예측하는데 있어서도 SCC Ag 단독측정보다 CYFRA 21-1와의 병행측정시 더 효용성이 있을 것으로 생각되지만 보다 많은 환자를 대상으로 장기간에 걸친 연구가 필요할 것으로 생각된다.
ko
dc.formatapplication/pdf-
dc.language.isoko-
dc.titleClinical value of pretreatment serum cyfra 21-1 and SCC Ag levels in cervical cancer patients-
dc.title.alternative자궁경부암 환자에서 종양표지물질 CYFRA 21-1과 SCC Ag의 치료전 혈청치의 유용성-
dc.typeArticle-
dc.subject.keywordSCC Ag-
dc.subject.keywordCYFRA 21-1-
dc.subject.keywordCervical cancer-
dc.subject.keywordTumor marker-
dc.subject.keyword자궁경부암-
dc.subject.keyword혈청 종양표지물질-
dc.contributor.affiliatedAuthor유, 희석-
dc.contributor.affiliatedAuthor장, 기홍-
dc.contributor.affiliatedAuthor전, 미선-
dc.contributor.affiliatedAuthor박, 찬희-
dc.contributor.affiliatedAuthor박, 영한-
dc.contributor.affiliatedAuthor오, 기석-
dc.type.localJournal Papers-
dc.citation.titleKorean journal of obstetrics and gynecology-
dc.citation.volume42-
dc.citation.number12-
dc.citation.date1999-
dc.citation.startPage2720-
dc.citation.endPage2725-
dc.identifier.bibliographicCitationKorean journal of obstetrics and gynecology, 42(12). : 2720-2725, 1999-
dc.relation.journalidJ004944755-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Obstetrics & Gynecology
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Humanities & Social Medicine
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Nuclear Medicine & Molecular Imaging
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse